Accéder au contenu principal

hfpef-diva

Publications

Previous relevant publications from HFpEF-DIVA team members:

  • Modulating Effect of Carbohydrate Antigen 125 on the Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure. Santas E, Martí-Martínez A, Revuelta-López E, Villar S, de la Espriella R, Palau P, Llàcer P, Miñana G, Rodriguez-Borja E, Carratalá A, Gonzalez A, Bayés-Genís A, Sanchis J, Núñez J. Biomolecules. 2025 ;15(9):1260. doi: 10.3390/biom15091260
  • Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Adamo M, Pagnesi M, Chioncel O, Bayes-Genis A, Abdelhamid M, Antohi EL, Bucciarelli-Ducci C, Chieffo A, Cosyns B, Gilard M, Grapsa J, González A, Gustafsson F, Iung B, Joner M, Karam N, Lund LH, Maisano F, Moura B, Praz F, Rudolph TK, Sannino A, Savarese G, Tocchetti CG, Van Empel VPM, Volterrani M, Windecker S, Ponikowski P, Rosano GMC, Barbato E, Metra M.
    Eur J Heart Fail. 2025 doi: 10.1002/ejhf.70023.
  • CCR2(+) monocyte-derived macrophages drive cardiac hypertrophy in early HFpEF. Jana Raman, Steven Simmonds, Ellen Caluwé, Rick van Leeuwen, Caroline Walschap, Mathias Stroobants, Ümare Cöl, Petra Vandervoort, Stephane Heymans, Elizabeth A V Jones. Am J Physiol Heart Circ Physiol. 2025 ;329(1):H109-H123. doi: 10.1152/ajpheart.00022.2025
  • Metabolic and Immune Crosstalk in Cardiovascular Disease. Mohanta SK, Heron C, Klaus-Bergmann A, Horstmann H, Brakenhielm E, Giannarelli C, Habenicht AJR, Gerhardt H, Weber C. Circ Res. 2025 ;136(11):1433-1453. doi: 10.1161/CIRCRESAHA.125.325496.
  • The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction. Mourmans SGJ, Achten A, Hermans R, Scheepers MJE, D'Alessandro E, Swennen G, Woudstra J, Appelman Y, Goor HV, Schalkwijk C, Knackstedt C, Weerts J, Eringa EC, van Empel VPM. Cardiovasc Diabetol. 2025 ;24(1):182. doi: 10.1186/s12933-025-02679-8.
  • Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling. Grootaert MOJ, Pasut A, Raman J, Simmonds SJ, Callewaert B, Col Ü, Dewerchin M, Carmeliet P, Heymans S, Jones EAV. Cardiovasc Diabetol. 2025 ;24(1):62. doi: 10.1186/s12933-025-02623-w
  • Pericyte loss initiates microvascular dysfunction in the development of diastolic dysfunction. Simmonds SJ, Grootaert MOJ, Cuijpers I, Carai P, Geuens N, Herwig M, Baatsen P, Hamdani N, Luttun A, Heymans S, Jones EAV. Eur Heart J Open. 2023 ;4(1):oead129. doi: 10.1093/ehjopen/oead129
  • Improving insights into the heterogeneous HFpEF syndrome through microvascular research. Weerts J, Mourmans SGJ, Eringa E, van Empel VPM. J Mol Cell Cardiol. 2022;167:106-108. doi: 10.1016/j.yjmcc.2022.04.001
  • The HFA-PEFF score identifies 'early-HFpEF' phenogroups associated with distinct biomarker profiles. Henkens MTHM, van Ommen AM, Remmelzwaal S, Valstar GB, Wang P, Verdonschot JAJ, Hazebroek MR, Hofstra L, van Empel VPM, Beulens JWJ, den Ruijter HM, Heymans SRB. ESC Heart Fail. 2022;9(3):2032-2036. doi: 10.1002/ehf2.13861.
  • Impact analysis of heart failure across European countries: an ESC-HFA position paper. Rosano GMC, Seferovic P, Savarese G, Spoletini I, Lopatin Y, Gustafsson F, Bayes-Genis A, Jaarsma T, Abdelhamid M, Miqueo AG, Piepoli M, Tocchetti CG, Ristić AD, Jankowska E, Moura B, Hill L, Filippatos G, Metra M, Milicic D, Thum T, Chioncel O, Ben Gal T, Lund LH, Farmakis D, Mullens W, Adamopoulos S, Bohm M, Norhammar A, Bollmann A, Banerjee A, Maggioni AP, Voors A, Solal AC, Coats AJS. ESC Heart Fail. 2022 ;9(5):2767-2778. doi: 10.1002/ehf2.14076.
  • Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Cuijpers I, Simmonds SJ, van Bilsen M, Czarnowska E, González Miqueo A, Heymans S, Kuhn AR, Mulder P, Ratajska A, Jones EAV, Brakenhielm E. Basic Res Cardiol. 2020 ;115(4):39. doi: 10.1007/s00395-020-0798-y.